Glucagonoma surgery: Difference between revisions

Jump to navigation Jump to search
(Mahshid)
 
(15 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Glucagonoma}}
{{Glucagonoma}}
{{CMG}}{{AE}}{{PSD}}
{{CMG}}; {{AE}} {{PSD}} {{MAD}}
==Overview==
==Overview==
Surgery is the mainstay of treatment for glucagonoma. The feasibility of surgery depends on the stage of glucagonoma at diagnosis.<ref name="pmid15313692">{{cite journal| author=Zhang M, Xu X, Shen Y, Hu ZH, Wu LM, Zheng SS| title=Clinical experience in diagnosis and treatment of glucagonoma syndrome. | journal=Hepatobiliary Pancreat Dis Int | year= 2004 | volume= 3 | issue= 3 | pages= 473-5 | pmid=15313692 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15313692  }} </ref>
Surgery is the mainstay of treatment for glucagonoma. The feasibility of surgery depends on the stage of glucagonoma at diagnosis. [[Hepatic]] resection is indicated for the treatment of metastatic liver disease in patients who are candidates for surgery with no extensive extrahepatic metastases.


==Surgery==
==Surgery==
Surgery is the mainstay of treatment for glucagonoma. The feasibility of surgery depends on the stage of glucagonoma at diagnosis.<ref name="pmid15313692">{{cite journal| author=Zhang M, Xu X, Shen Y, Hu ZH, Wu LM, Zheng SS| title=Clinical experience in diagnosis and treatment of glucagonoma syndrome. | journal=Hepatobiliary Pancreat Dis Int | year= 2004 | volume= 3 | issue= 3 | pages= 473-5 | pmid=15313692 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15313692  }} </ref><ref>Pancreatic Neuroendocrine Tumors (Islet Cell Tumors). National Cancer Institute. http://www.cancer.gov/types/pancreatic/hp/pnet-treatment-pdq#section/_88</ref>
 
*Single, small lesion in head or tail of pancreas:
=== Management of primary disease ===
*:Enucleation, if feasible
* [[Surgery]] is the mainstay of treatment for glucagonoma.
*Large lesion in the head of the pancreas that is not amenable to enucleation:
* [[Resection]] of the primary [[pancreatic tumor]] is indicated if the tumor is resectable in good general condition patients. It offers the chance of complete cure.<ref name="pmid8628004">{{cite journal| author=Smith AP, Doolas A, Staren ED| title=Rapid resolution of necrolytic migratory erythema after glucagonoma resection. | journal=J Surg Oncol | year= 1996 | volume= 61 | issue= 4 | pages= 306-9 | pmid=8628004 | doi=10.1002/(SICI)1096-9098(199604)61:4<306::AID-JSO15>3.0.CO;2-3 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8628004  }}</ref>
:*Pancreaticoduodenectomy
* Preoperative management: [[total parenteral nutrition]] may be required before the [[surgery]]. Infusions of [[Amino acid|amino]] and [[fatty acids]] reduce symptoms and improve survival rates.<ref name="pmid12460334">{{cite journal| author=Alexander EK, Robinson M, Staniec M, Dluhy RG| title=Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome. | journal=Clin Endocrinol (Oxf) | year= 2002 | volume= 57 | issue= 6 | pages= 827-31 | pmid=12460334 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12460334  }}</ref>
*Single, large lesion in body/tail:
*The feasibility of [[surgery]] depends on the stage of glucagonoma at diagnosis.<ref name="pmid15313692">{{cite journal| author=Zhang M, Xu X, Shen Y, Hu ZH, Wu LM, Zheng SS| title=Clinical experience in diagnosis and treatment of glucagonoma syndrome. | journal=Hepatobiliary Pancreat Dis Int | year= 2004 | volume= 3 | issue= 3 | pages= 473-5 | pmid=15313692 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15313692  }} </ref><ref>Pancreatic Neuroendocrine Tumors (Islet Cell Tumors). National Cancer Institute. http://www.cancer.gov/types/pancreatic/hp/pnet-treatment-pdq#section/_88</ref>
:*Distal pancreatectomy
**Single, small lesion in head or tail of [[pancreas]]: [[Enucleation]], if feasible
*Multiple lesions:
**Large lesion in the head of the pancreas that is not amenable to enucleation: [[Pancreaticoduodenectomy]]
:*Enucleation, if feasible
**Single, large lesion in body/tail: [[Pancreatectomy|distal pancreatectom<nowiki/>y]]
:*Resect body and tail otherwise
**Multiple lesions: [[Enucleation]], if feasible
*Metastatic disease: lymph nodes or distant sites:
 
:*Resect when possible
=== Management of metastasis ===
:*Consider radiofrequency or cryosurgical ablation, if not resectable
[[Hepatic]] resection is indicated for the treatment of metastatic liver disease in patients who are candidates for surgery with no extensive extrahepatic metastases. It may potentially increase survival and has the benefit of symptom [[palliation]].<ref name="pmid1701060">{{cite journal| author=McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS| title=Cytoreductive hepatic surgery for neuroendocrine tumors. | journal=Surgery | year= 1990 | volume= 108 | issue= 6 | pages= 1091-6 | pmid=1701060 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1701060  }}</ref>
*Unresectable disease:
:*Combination chemotherapy
:*Somatostatin analogue therapy. Necrotizing erythema of glucagonoma may be relieved in 24 hours with somatostatin analogue, with nearly complete disappearance within 1 week


==References==
==References==
{{reflist|2}}
{{reflist|2}}
 
{{WH}}
[[Category:Disease]]
{{WS}}
[[Category:Types of cancer]]
[[Category:Medicine]]
[[Category:Endocrinology]]
[[Category:Endocrinology]]
[[Category:Needs content]]
[[Category:Up-To-Date]]
 
[[Category:Oncology]]
{{WikiDoc Help Menu}}
[[Category:Medicine]]
{{WikiDoc Sources}}
[[Category:Gastroenterology]]
[[Category:Surgery]]

Latest revision as of 01:49, 27 November 2017

Glucagonoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Glucagonoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glucagonoma surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glucagonoma surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glucagonoma surgery

CDC on Glucagonoma surgery

Glucagonoma surgery in the news

Blogs on Glucagonoma surgery

Directions to Hospitals Treating Glucagonoma

Risk calculators and risk factors for Glucagonoma surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2] Mohammed Abdelwahed M.D[3]

Overview

Surgery is the mainstay of treatment for glucagonoma. The feasibility of surgery depends on the stage of glucagonoma at diagnosis. Hepatic resection is indicated for the treatment of metastatic liver disease in patients who are candidates for surgery with no extensive extrahepatic metastases.

Surgery

Management of primary disease

Management of metastasis

Hepatic resection is indicated for the treatment of metastatic liver disease in patients who are candidates for surgery with no extensive extrahepatic metastases. It may potentially increase survival and has the benefit of symptom palliation.[5]

References

  1. Smith AP, Doolas A, Staren ED (1996). "Rapid resolution of necrolytic migratory erythema after glucagonoma resection". J Surg Oncol. 61 (4): 306–9. doi:10.1002/(SICI)1096-9098(199604)61:4<306::AID-JSO15>3.0.CO;2-3. PMID 8628004.
  2. Alexander EK, Robinson M, Staniec M, Dluhy RG (2002). "Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome". Clin Endocrinol (Oxf). 57 (6): 827–31. PMID 12460334.
  3. Zhang M, Xu X, Shen Y, Hu ZH, Wu LM, Zheng SS (2004). "Clinical experience in diagnosis and treatment of glucagonoma syndrome". Hepatobiliary Pancreat Dis Int. 3 (3): 473–5. PMID 15313692.
  4. Pancreatic Neuroendocrine Tumors (Islet Cell Tumors). National Cancer Institute. http://www.cancer.gov/types/pancreatic/hp/pnet-treatment-pdq#section/_88
  5. McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS (1990). "Cytoreductive hepatic surgery for neuroendocrine tumors". Surgery. 108 (6): 1091–6. PMID 1701060.

Template:WH Template:WS